×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
LON:MXC

MGC Pharmaceuticals (MXC) Share Forecast, Price & News

GBX 1.10
0.00 (0.00%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
1.05
1.15
50-Day Range
1.10
1.44
52-Week Range
1.02
3.95
Volume
5.53 million shs
Average Volume
4.33 million shs
Market Capitalization
£29.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive MXC News and Ratings via Email

Sign-up to receive the latest news and ratings for MGC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About MGC Pharmaceuticals

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Crude Petroleum and Natural Gas Extraction
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Sales & Book Value

Annual Sales
£4.79 million
Cash Flow
GBX 0.30 per share
Book Value
GBX 0.70 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
2,719,332,000
Free Float
N/A
Market Cap
£29.91 million
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.03 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













MGC Pharmaceuticals (LON:MXC) Frequently Asked Questions

Is MGC Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MGC Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MGC Pharmaceuticals stock.
View analyst ratings for MGC Pharmaceuticals
or view top-rated stocks.

What price target have analysts set for MXC?

1 equities research analysts have issued 12-month target prices for MGC Pharmaceuticals' shares. Their forecasts range from GBX 7.20 to GBX 7.20. On average, they anticipate MGC Pharmaceuticals' share price to reach GBX 7.20 in the next year. This suggests a possible upside of 554.5% from the stock's current price.
View analysts' price targets for MGC Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are MGC Pharmaceuticals' key executives?
MGC Pharmaceuticals' management team includes the following people:
  • Mr. Brett Anthony Mitchell B.Ec., MAICD, Exec. Chairman (Age 49, Pay $229.57k)
  • Mr. Roby Reuven Zomer, Interim CFO, Co-Founder, CEO, MD & Exec. Director (Age 41, Pay $232.13k)
  • Mr. Nativ Segev, Founder & Non-Exec. Director
  • Ms. Sasha Friedman, Deputy CEO & COO
  • Mr. Amir Polak, Chief Technology Officer
  • Ms. Nicole Ann Godresse, Global Chief Sales Officer
  • Ms. Sabina Suljakovic, Head of the Quality Assurance Department
  • Dr. Nadya Lisodover, Chief Medical Officer
  • Yair Tal, Chief Security Officer
  • Hugh Winters, Chief Exec. Officer of MGC Derma
What is MGC Pharmaceuticals' stock symbol?

MGC Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "MXC."

How do I buy shares of MGC Pharmaceuticals?

Shares of MXC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is MGC Pharmaceuticals' stock price today?

One share of MXC stock can currently be purchased for approximately GBX 1.10.

How much money does MGC Pharmaceuticals make?

MGC Pharmaceuticals has a market capitalization of £29.91 million and generates £4.79 million in revenue each year.

How many employees does MGC Pharmaceuticals have?

MGC Pharmaceuticals employs 4 workers across the globe.

What is MGC Pharmaceuticals' official website?

The official website for MGC Pharmaceuticals is www.mexcoenergy.com.

How can I contact MGC Pharmaceuticals?

MGC Pharmaceuticals' mailing address is 415 W Wall St Ste 475, Midland, Texas 79701-4482. The company can be reached via phone at 19156821119.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.